Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
Public ClinicalTrials.gov record NCT00244751. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Study identification
- NCT ID
- NCT00244751
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- GlaxoSmithKline
- Industry
- Enrollment
- 265 participants
Conditions and interventions
Conditions
Interventions
- GI262570 0.5 mg Drug
- GI262570 1.0 mg Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 40 Years to 70 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 1, 2005
- Primary completion
- Mar 12, 2008
- Completion
- Mar 12, 2008
- Last update posted
- Dec 10, 2017
2005 – 2008
United States locations
- U.S. sites
- 58
- U.S. states
- 23
- U.S. cities
- 48
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| GSK Investigational Site | Birmingham | Alabama | 35294-0005 | — |
| GSK Investigational Site | Tucson | Arizona | 85719 | — |
| GSK Investigational Site | North Little Rock | Arkansas | 72117 | — |
| GSK Investigational Site | Bakersfield | California | 93301 | — |
| GSK Investigational Site | La Jolla | California | 92024 | — |
| GSK Investigational Site | Los Angeles | California | 90048 | — |
| GSK Investigational Site | Los Angeles | California | 90095 | — |
| GSK Investigational Site | Newport Beach | California | 92663 | — |
| GSK Investigational Site | Pasadena | California | 91105 | — |
| GSK Investigational Site | Sacramento | California | 95825 | — |
| GSK Investigational Site | San Clemente | California | 92673 | — |
| GSK Investigational Site | San Francisco | California | 94121 | — |
| GSK Investigational Site | Santa Clara | California | 95051 | — |
| GSK Investigational Site | Englewood | Colorado | 80113 | — |
| GSK Investigational Site | Washington D.C. | District of Columbia | 20010 | — |
| GSK Investigational Site | Fort Lauderdale | Florida | 33308 | — |
| GSK Investigational Site | Miami | Florida | 33136 | — |
| GSK Investigational Site | Orlando | Florida | 32804 | — |
| GSK Investigational Site | Sarasota | Florida | 34243 | — |
| GSK Investigational Site | Atlanta | Georgia | 30033 | — |
| GSK Investigational Site | Atlanta | Georgia | 30308 | — |
| GSK Investigational Site | Atlanta | Georgia | 30309 | — |
| GSK Investigational Site | Marietta | Georgia | 30060 | — |
| GSK Investigational Site | Honolulu | Hawaii | 96817 | — |
| GSK Investigational Site | Indianapolis | Indiana | 46202 | — |
| GSK Investigational Site | Iowa City | Iowa | 52242 | — |
| GSK Investigational Site | Louisville | Kentucky | 40202 | — |
| GSK Investigational Site | Lutherville-Timonium | Maryland | 21093 | — |
| GSK Investigational Site | Boston | Massachusetts | 02111 | — |
| GSK Investigational Site | Boston | Massachusetts | 02114 | — |
| GSK Investigational Site | Boston | Massachusetts | 02215 | — |
| GSK Investigational Site | Worcester | Massachusetts | 01655 | — |
| GSK Investigational Site | Ann Arbor | Michigan | 48109 | — |
| GSK Investigational Site | Detroit | Michigan | 48202 | — |
| GSK Investigational Site | St Louis | Missouri | 63104 | — |
| GSK Investigational Site | Binghamton | New York | 13901 | — |
| GSK Investigational Site | Manhasset | New York | 11030 | — |
| GSK Investigational Site | New York | New York | 10003 | — |
| GSK Investigational Site | New York | New York | 10021 | — |
| GSK Investigational Site | New York | New York | 10029 | — |
| GSK Investigational Site | New York | New York | 10032 | — |
| GSK Investigational Site | Syracuse | New York | 13210 | — |
| GSK Investigational Site | The Bronx | New York | 10468 | — |
| GSK Investigational Site | Chapel Hill | North Carolina | 27599 | — |
| GSK Investigational Site | Durham | North Carolina | 27710 | — |
| GSK Investigational Site | Cincinnati | Ohio | 45219 | — |
| GSK Investigational Site | Cincinnati | Ohio | 45267-0595 | — |
| GSK Investigational Site | Cleveland | Ohio | 44195 | — |
| GSK Investigational Site | Tulsa | Oklahoma | 74104 | — |
| GSK Investigational Site | Hershey | Pennsylvania | 17033-0850 | — |
| GSK Investigational Site | Lancaster | Pennsylvania | 17604-3200 | — |
| GSK Investigational Site | Dallas | Texas | 75390-8887 | — |
| GSK Investigational Site | Houston | Texas | 77030 | — |
| GSK Investigational Site | San Antonio | Texas | 78215 | — |
| GSK Investigational Site | Charlottesville | Virginia | 22908 | — |
| GSK Investigational Site | Fairfax | Virginia | 22031 | — |
| GSK Investigational Site | Richmond | Virginia | 23249 | — |
| GSK Investigational Site | Richmond | Virginia | 23298 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 63 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00244751, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 10, 2017 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00244751 live on ClinicalTrials.gov.